Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sector perform” rating reissued by equities researchers at Royal Bank of Canada in a note issued to investors on Tuesday, MarketBeat reports. They currently have a $142.00 price target on the biotechnology company’s stock, down from their prior price target of $157.00. Royal Bank of […]